A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in #LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #CART #celltherapy #allogeneic $ALLO Learn More About ALPHA3: allogene.com/alpha3/

As @ScienceMagazine asks whether #allogeneic #CART can deliver, the picture is coming into focus. Our #ALPHA3 interim futility analysis suggests our investigational candidate may help eliminate #MRD after 1L treatment in #LBCL. $ALLO Read More: science.org/content/blog-pos…

We aim to redefine #autoimmune disease treatment with ALLO-329, an investigational allogeneic #CART powered by Dagger® technology, which is designed to reduce or eliminate lymphodepletion. #celltherapy #allogeneic $ALLO Uncover the Potential of ALLO-329: Allogene.com/Pipeline

Allogene was proud to sponsor Friends of Cancer Research's 30th Anniversary Celebration in Washington, DC, honoring three decades of collaboration to advance cancer research and improve outcomes for patients. Congratulations to the Friends team on this milestone. $ALLO #oncology

Updated NCCN myeloma guidelines now recommend annual #MRD testing, a signal that MRD-guided care is gaining ground. In #ALPHA3, we go further: using MRD as a treatment decision trigger for intervention in 1L #LBCL, not just monitoring. #CART #allogeneic $ALLO Read More: onclive.com/view/updated-ncc…

Brining #CART to community settings is one of oncology's most urgent challenges. The #ALPHA3 trial is designed to overcome access barriers and enable treatment where patients already receive care. @AJMC_Journal explores what it takes. #LBCL. #allogeneic #celltherapy $ALLO Read More: ajmc.com/view/building-commu…

1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO Learn More About ALPHA3: allogene.com/alpha3/

As #BloodCancerAwarenessMonth closes, we're proud of how the Allogene team showed up through #AllogeneGives. Blood donated. Awareness raised. And as we head toward Light the Night in November, our commitment to the blood cancer community only grows. Learn More: Allogene.com/Home

At Allogene, we’re advancing #CART therapy to transform lives. Through bold innovation in #celltherapy, we’re working to expand access and redefine what’s possible for patients. Follow us to learn more. #allogeneic $ALLO Learn More: Allogene.com/Home

Experience the #allogeneic advantage. Our investigational AlloCAR T products aim to redefine the #CART landscape by addressing key limitations of autologous treatments – offering the potential for greater speed, scalability, and access for patients. #celltherapy $ALLO Discover the Allogeneic Advantage: Allogene.com/Home

Huge congratulations to Dr. Malcolm Brenner and the team @bcmhouston. Solid tumors have long been one of CAR T’s toughest frontiers. Work like this is another reason to believe that difficult does not mean impossible. We’ve seen encouraging signs in our own solid tumor work at Allogene. Progress like this adds to a growing body of evidence that CAR T can break through in solid tumors.

Allogene is advancing ALLO-329 – an investigational off-the-shelf AlloCAR T product for #autoimmune disease, powered by our proprietary Dagger® technology. See how we’re aiming to reset the immune system, expand access and transform care. #CART #celltherapy #allogeneic $ALLO

We believe the promise of #CART isn't complete until it can reach the patients who need it – wherever they are. An excellent reminder that innovation and #patientaccess must move together. Read the full piece here: survivornet.com/articles/all… #celltherapy #oncology @SurvivorNetTeam

1 in 3 #LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an off-the-shelf #CART product to intervene early and potentially improve cure rates. $ALLO Learn More About ALPHA3: allogene.com/alpha3

New @BloodAdvances data show 14% of #LBCL patients die after starting 1L treatment. In 2L, just 15% receive #CAR T. With 75% treated in community settings, structural barriers limit access. The #ALPHA3 trial aims to bring allogenenic CAR T closer to patients. $ALLO #oncology Learn More About ALPHA3: allogene.com/alpha3/

It's been a milestone year in our work to bring AlloCAR T closer to patients. For #BloodCancerAwarenessMonth this September, we are channeling that momentum through #AllogeneGives, showing up for the blood cancer community beyond the lab. $ALLO #CART #celltherapy Learn More: Allogene.com/Home

Tomorrow, Allogene will be at the @Citi Biopharma Back to School Conference in New York, sharing updates on our pipeline and corporate strategy. Webcast details are available in the Investors section of our website. $ALLO #CART #celltherapy #biotech

Allogene will participate in upcoming fall investor conferences, sharing updates on our investigational pipeline and corporate strategy. Webcast details are available in the Investors section of our website. $ALLO #CART #celltherapy #Biotechnology Learn More: ir.allogene.com/news-release…

At Allogene, we’re advancing #CART therapy to transform lives. Through bold innovation in #celltherapy, we’re working to expand access and redefine what’s possible for patients. Follow us to learn more. #allogeneic $ALLO Learn More: Allogene.com/Home